SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 98-108

  Nordström, Lena ^a   Sernbo, Sandra ^a   Eden, Patrik ^b   Grønbæk, Kirsten ^c   Kolstad, Arne ^d   Räty, Riikka ^e   Karjalainen, Marja Liisa ^e   Geisler, Christian ^c   Ralfkiær, Elisabeth ^c   Sundström, Christer ^f   Laurell, Anna ^g   Delabie, Jan ^h   Ehinger, Mats ⁱ   Jerkeman, Mats ⁱ   Ek, Sara ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c University of Copenhagen   (Denmark)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UPPSALA UNIVERSITY   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Lymphoid malignancies; Molecular diagnostics; Prognostic factors

Indexed keywords

CYCLIN D1; CYTARABINE; KI 67 ANTIGEN; MOLECULAR MARKER; PROTEIN P53; RITUXIMAB; TRANSCRIPTION FACTOR SOX11;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

LYMPHOID MALIGNANCIES; MOLECULAR DIAGNOSTICS; PROGNOSTIC FACTORS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COHORT STUDIES; CYCLIN D1; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SOXC TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902333158     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12854     Document Type: Article

References (34)

1. Akaike, H. (1974) A new look at the statistical model identification. IEEE Transactions on Automatic Control, 19, 716-723.
2. Bernard, M., Gressin, R., Lefrere, F., Drenou, B., Branger, B., Caulet-Maugendre, S., Tass, P., Brousse, N., Valensi, F., Milpied, N., Voilat, L., Sadoun, A., Ghandour, C., Hunault, M., Leloup, R., Mannone, L., Hermine, O. Lamy, T. (2001) Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia, 15, 1785-1791.
3. Chen, Y.H., Gao, J., Fan, G. Peterson, L.C. (2010) Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Modern Pathology, 23, 105-112.
4. Conrotto, P., Andreasson, U., Kuci, V., Borrebaeck, C.A. Ek, S. (2011) Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo. Molecular Oncology, 5, 527-537.
5. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society Series B: Methodological, 34, 187-220.
6. Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., Tilly, H., Salles, G., Van Hoof, A., Casasnovas, O., Brousse, N., Lefrere, F., Hermine, O. Groupe d'Etude des Lymphomes de l'Adulte (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood, 121, 48-53.
7. Dreyling, M., Kluin-Nelemans, H.C., Bea, S., Klapper, W., Vogt, N., Delfau-Larue, M.H., Hutter, G., Cheah, C., Chiappella, A., Cortelazzo, S., Pott, C., Hess, G., Visco, C., Vitolo, U., Klener, P., Aurer, I., Unterhalt, M., Ribrag, V., Hoster, E., Hermine, O. European Mantle Cell Lymphoma Network (2013) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leukaemia Lymphoma, 54, 699-707.
8. Ek, S., Dictor, M., Jerkeman, M., Jirstrom, K. Borrebaeck, C.A. (2008) Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 111, 800-805.
9. Fernandez, V., Salamero, O., Espinet, B., Sole, F., Royo, C., Navarro, A., Camacho, F., Bea, S., Hartmann, E., Amador, V., Hernandez, L., Agostinelli, C., Sargent, R.L., Rozman, M., Aymerich, M., Colomer, D., Villamor, N., Swerdlow, S.H., Pileri, S.A., Bosch, F., Piris, M.A., Montserrat, E., Ott, G., Rosenwald, A., Lopez-Guillermo, A., Jares, P., Serrano, S. Campo, E. (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Research, 70, 1408-1418.
10. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundstrom, C., Langholm, R., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P., Elonen, E. Nordic Lymphoma Group (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687-2693.
11. Geisler, C.H., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., Eriksson, M., Nordstrom, M., Kimby, E., Boesen, A.M., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G.F., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P., Elonen, E. Nordic Lymphoma Group (2010) The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 115, 1530-1533.
12. Geisler, C.H., Kolstad, A., Laurell, A., Jerkeman, M., Raty, R., Andersen, N.S., Pedersen, L.B., Eriksson, M., Nordstrom, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Ehinger, M., Sundstrom, C., Delabie, J., Karjalainen-Lindsberg, M.L., Brown, P. Elonen, E. (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology, 158, 355-362.
13. Gustavsson, E., Sernbo, S., Andersson, E., Brennan, D.J., Dictor, M., Jerkeman, M., Borrebaeck, C.A. Ek, S. (2010) SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies. Molecular Cancer, 9, 187.
14. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wormann, B., Trumper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511-518.
15. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., Van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wormann, B., Ludwig, W.D., Duhrsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W., Unterhalt, M. German Low Grade Lymphoma Study Group and European Mantle Cell Lymphoma Network (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111, 558-565.
16. Kolstad, A., Laurell, A., Jerkeman, M., Gronbaek, K., Elonen, E., Raty, R., Pedersen, L.B., Loft, A., Bogsrud, T.V., Nordstrom, M., Hansen, P.B., Fagerli, U.-M., Nilsson-Ehle, H., Lauritzsen, G.F., Lehmann, A.K., Sundstrom, C., Karjalainen-Lindsberg, M.-L., Ralfkiaer, E., Ehinger, M., Delabie, J., Bentzen, H., Schildt, J., Kostova-Aherdan, K., Frederiksen, H., De Nully Brown, P. Geisler, C.H. (2012) Nordic MCL3 Study: Zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients < 66 years not in CR after induction chemoimmunotherapy: no benefit of Zevalin. Blood (ASH Annual Meeting Abstracts), 120, 747.
17. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M.J., Sauter, G. Kallioniemi, O.P. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 4, 844-847.
18. Louie, D.C., Offit, K., Jaslow, R., Parsa, N.Z., Murty, V.V., Schluger, A. Chaganti, R.S. (1995) p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood, 86, 2892-2899.
19. Mozos, A., Royo, C., Hartmann, E., De Jong, D., Baro, C., Valera, A., Fu, K., Weisenburger, D.D., Delabie, J., Chuang, S.S., Jaffe, E.S., Ruiz-Marcellan, C., Dave, S., Rimsza, L., Braziel, R., Gascoyne, R.D., Sole, F., Lopez-Guillermo, A., Colomer, D., Staudt, L.M., Rosenwald, A., Ott, G., Jares, P. Campo, E. (2009) SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica, 94, 1555-1562.
20. Navarro, A., Clot, G., Royo, C., Jares, P., Hadzidimitriou, A., Agathangelidis, A., Bikos, V., Darzentas, N., Papadaki, T., Salaverria, I., Pinyol, M., Puig, X., Palomero, J., Vegliante, M.C., Amador, V., Martinez-Trillos, A., Stefancikova, L., Wiestner, A., Wilson, W., Pott, C., Calasanz, M.J., Trim, N., Erber, W., Sander, B., Ott, G., Rosenwald, A., Colomer, D., Gine, E., Siebert, R., Lopez-Guillermo, A., Stamatopoulos, K., Bea, S. Campo, E. (2012) Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Research, 72, 5307-5316.
21. Nordstrom, L., Andreasson, U., Jerkeman, M., Dictor, M., Borrebaeck, C. Ek, S. (2012) Expanded clinical and experimental use of SOX11 - using a monoclonal antibody. BMC Cancer, 12, 269.
22. Nygren, L., Baumgartner Wennerholm, S., Klimkowska, M., Christensson, B., Kimby, E. Sander, B. (2012) Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood, 119, 4215-4223.
23. Oka, K., Ohno, T., Kita, K., Yamaguchi, M., Takakura, N., Nishii, K., Miwa, H. Shirakawa, S. (1994) PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. British Journal of Haematology, 86, 786-791.
24. Romaguera, J.E., Fayad, L.E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M.A., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Cabanillas, F., Kantarjian, H., Kwak, L. Wang, M. (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Haematology, 150, 200-208.
25. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. Staudt, L.M. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185-197.
26. Royo, C., Navarro, A., Clot, G., Salaverria, I., Gine, E., Jares, P., Colomer, D., Wiestner, A., Wilson, W.H., Vegliante, M.C., Fernandez, V., Hartmann, E.M., Trim, N., Erber, W.N., Swerdlow, S.H., Klapper, W., Dyer, M.J., Vargas-Pabon, M., Ott, G., Rosenwald, A., Siebert, R., Lopez-Guillermo, A., Campo, E. Bea, S. (2012) Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia, 26, 1895-1898.
27. Salaverria, I., Royo, C., Carvajal-Cuenca, A., Clot, G., Navarro, A., Valera, A., Song, J.Y., Woroniecka, R., Rymkiewicz, G., Klapper, W., Hartmann, E.M., Sujobert, P., Wlodarska, I., Ferry, J.A., Gaulard, P., Ott, G., Rosenwald, A., Lopez-Guillermo, A., Quintanilla-Martinez, L., Harris, N.L., Jaffe, E.S., Siebert, R., Campo, E. Bea, S. (2013) CCND2 rearrangements are the most frequent genetic events in Cyclin D1-negative mantle cell lymphoma. Blood, 121, 1394-1402.
28. Slotta-Huspenina, J., Koch, I., De Leval, L., Keller, G., Klier, M., Bink, K., Kremer, M., Raffeld, M., Fend, F. Quintanilla-Martinez, L. (2012) The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica, 97, 1422-1430.
29. Stefancikova, L., Moulis, M., Fabian, P., Ravcukova, B., Vasova, I., Muzik, J., Malcikova, J., Falkova, I., Slovackova, J. Smardova, J. (2010) Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. International Journal of Oncology, 36, 699-706.
30. Vegliante, M.C., Palomero, J., Perez-Galan, P., Roue, G., Castellano, G., Navarro, A., Clot, G., Moros, A., Suarez-Cisneros, H., Bea, S., Hernandez, L., Enjuanes, A., Jares, P., Villamor, N., Colomer, D., Martin-Subero, J.I., Campo, E. Amador, V. (2013) SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood, 121, 2175-2185.
31. Wang, X., Asplund, A.C., Porwit, A., Flygare, J., Smith, C.I., Christensson, B. Sander, B. (2008) The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. British Journal of Haematology, 143, 248-252.
32. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369, 507-516.
33. Weisenburger, D.D. Armitage, J.O. (1996) Mantle cell lymphoma- an entity comes of age. Blood, 87, 4483-4494.
34. Yatabe, Y., Suzuki, R., Tobinai, K., Matsuno, Y., Ichinohasama, R., Okamoto, M., Yamaguchi, M., Tamaru, J., Uike, N., Hashimoto, Y., Morishima, Y., Suchi, T., Seto, M. Nakamura, S. (2000) Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood, 95, 2253-2261.